Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,947 DKK | -0.35% | +0.54% | -9.74% |
11:54am | Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating | MT |
06-03 | Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.74% | 18.32B | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+1.37% | 22.48B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B | |
+80.51% | 9.02B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'